Inhaled pharmaceuticals company Prosonix has announced the appointment of Columbia Laboratories President and CEO Frank Condella as a Non-executive Director of Prosonix. Condella has held numerous position in the pharmaceutical industry, including as CEO of SkyePharma from 2006 to 2008 and President of European Operations and Managing Director, UK at IVAX Corporation from 2002 to 2006. He is currently Non-Executive Chairman of SkyePharma.
Condella commented, “Prosonix has developed a unique platform for developing generic and novel respiratory medicines based on engineering drug particles whose fundamental properties are designed specifically for inhalation via simple inhalation devices. This approach could lead to the availability of the first directly substitutable generic respiratory medicines, as well as novel combination products with enhanced performance and cost benefits. Prosonix is a very exciting company and I am very much looking forward to working with the company during this transformational phase of its development.”
Prosonix Non-Executive Chairman Ken Cunningham added, “Prosonix has been successful in recruiting people with important and complementary industry experience to add to its management, board and advisory committee over the past 18 months so as to take full advantage of the commercial opportunity that its generic and novel respiratory drug candidates have the potential to address. We are therefore very pleased that Frank has joined the Prosonix Board. We anticipate his wide-ranging experience in developing and commercializing respiratory and other specialty medicines will prove valuable as we advance our lead programs towards the market.”
Read the Prosonix press release.
